Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Helius Appoints Chief Operating Officer

Mary Alice Simon has been appointed Chief Operating Officer (COO) at Helius Therapeutics - New Zealand’s largest licenced medicinal cannabis company.

Ms Simon joins Helius with extensive experience in the pharmaceuticals industry - both in Operations and Quality Assurance. Most recently, she was Head of Operations - Healthcare at API Consumer Brands, following four years as Head of Quality overseeing API’s pharmaceutical and personal care manufacturing plants in Auckland.

Previously, she was Head of Quality Assurance at Diatranz Otsuka Limited - formerly Living Cell Technologies. She also spent five years as Director of Data Management and Process Improvement at Penobscot Community Health Care in the United States.

She has an MBA from the University of Maine, as well as a Master of Science in Microbiology and a Bachelor of Science in Biochemistry.

Skilled in pharmaceutics and biotechnology, Ms Simon’s previous roles in the US were as Quality Assurance Specialist, Research Scientist, Validation Engineer, Quality Control Manager, and Technical Writer.

“We’re delighted to have Mary Alice join our internationally-experienced team at Helius. She intrinsically understands advanced manufacturing environments and the absolute quality assurance required in controlled medicines production,” says Carmen Doran, Chief Executive of Helius Therapeutics, who was the company’s previous COO.

As Chief Operating Officer at Helius, Ms Simon will substantially contribute to the organisation focused squarely on pharmaceuticals manufacturing, cannabis-based medicines research and development, quality systems and standards (GMP), and plant science.

“As well as delivering ongoing production capability and process improvements, I am looking forward to contributing to Helius’ world-leading innovation and quality rigour. Also exciting is the commercialisation of incredibly efficacious ‘New Zealand Made’ cannabis-based medicines which will soon be available for patients here and overseas,” says Ms Simon.

Last month, Helius announced it had raised a further $15m from private investors, with the Kiwi-owned company so far attracting nearly $50 million in investment. Helius has now completed its $20 million-plus state-of-the-art, integrated medicines manufacturing facility in East Auckland.

“Our latest capital raise enables Helius to start manufacturing pharmaceuticals, while undertaking New Zealand’s first clinical trials, reinforcing our commitment to advancing the safety and efficacy of medicinal cannabis products. Improving patients’ quality of life is at the heart of Helius, and we have the talent to deliver,” says Carmen Doran.

About Helius

Helius is a New Zealand-owned biotechnology company focused on medicinal cannabis research, innovation, manufacturing and commercialisation. It is the country’s largest licensed producer and the first medicinal cannabis cultivator to be certified as New Zealand Grown through the Buy NZ Made Campaign. The company operates a state-of-the-art, integrated facility in Auckland with indoor controlled growing systems, extraction site, an advanced cannabinoid research laboratory and manufacturing operations. Following changes to New Zealand’s regulatory environment, Helius is poised to set the standard for effective and accessible medicinal cannabis products in New Zealand and beyond.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Reserve Bank: Policy Lessons From A Year Of Covid-19

The Reserve Bank of New Zealand – Te Pūtea Matua was in a sound position to continue to meet its mandate in the face of the COVID-19 induced economic shock. However, we must continue to transform so as to remain relevant and effective in addressing longer-term challenges, Reserve Bank Governor Adrian Orr said... More>>

Transport Industry Association: Feb 2021 New Vehicle Registrations Strongest On Record

Motor Industry Association Chief Executive David Crawford says that the February 2021 figures are the strongest for the month of February ever. Registrations of 12,358 were 8.0% up on February 2020. Year to date the market is up 7.1% (1,735 units) compared to the first two months of 2020... More>>

Paymark: Lockdown Equals Slowdown For Some

The three days of lockdown for Auckland earlier this month made a clear impression on our retail spending figures. While only Auckland moved into Level 3 lockdown, the impact was felt across the country, albeit at different levels. Looking at the ... More>>

Infrastructure Commission: Te Waihanga Releases Report On Water Infrastructure

The New Zealand Infrastructure Commission, Te Waihanga’s latest discussion document highlights the importance of current reforms in the water sector. Its State of Play discussion document about water infrastructure is one of a series looking at the ... More>>

OECD: Annual Inflation Picks Up To 1.5% In January 2021 While Euro Area Records Sharp Increase To 0.9%

Annual inflation in the OECD area picked up to 1.5% in January 2021, compared with 1.2% in December 2020. Following a rebound between December and January, the annual decline in energy prices was less pronounced in January (minus 3.9%) than in December... More>>

Hemp Industries Association: Could The Next Team NZ Boat Be Made Entirely Of Hemp?

With The America’s Cup due to start in a few days’ time, innovators from a very different sphere have been wondering how long it could be before New Zealand could be competing in a boat entirely built from hemp, with the crew eating high-energy, nutritious hemp-infused foods and wearing high-performance hemp kit..? More>>

ACT: Matariki Almost A Half Billion Dollar Tax On Business

“Official advice to the Government says an extra public holiday at Matariki could cost almost $450 million,” ACT Leader David Seymour can reveal. “This is a perfect example of the Prime Minister doing what’s popular versus what’s responsible. ... More>>

Genesis: Assessing 6,000 GWh Of Renewable Generation Options For Development By 2025

Genesis is assessing 6,000 GWh of renewable generation options for development after starting a closed RFP process with 11 partners. Those invited to participate offer a range of technologies as Genesis continues to execute its Future-gen strategy to ... More>>